EDBI

EDBI is the strategic investment arm of the Singapore Economic Development Board, headquartered in Singapore with a global mandate and a long track record of backing cutting-edge biopharma, life sciences tools, and AI/ML healthcare platforms. The firm deploys $5M-$25M cheques at Series A, Series B, Series C, and growth, and combines patient growth capital with the Singapore EDB ecosystem advantage including R&D incentives, manufacturing infrastructure, and access to Asian regulatory and clinical pathways. For founders, EDBI is best positioned as a strategic Asia-focused growth lead with national-economic patient capital and meaningful regulatory navigation support, particularly valuable for biopharma, life sciences tools, and AI healthcare founders contemplating Singapore as a regional hub for R&D, manufacturing, or commercial operations. The right founder profile is a Series A-or-later operator (often US or European-headquartered) building a defensible biopharma, life sciences platform, or AI clinical product with a credible thesis on Asian market entry and willingness to commit meaningful Singapore-based footprint. Founders running consumer wellness, asset-heavy clinic chains, or platforms without serious R&D or scientific depth are a poor fit. The cleanest entry path is via the EDB ecosystem (Singapore-based corporate and academic networks), an EDBI portfolio CEO, or sell-side bankers with global biopharma practice depth. In the pitch, lead with scientific defensibility, regulatory pathway, Asian commercial strategy, and a credible plan to leverage Singapore’s R&D and manufacturing ecosystem. Caveats: as a state-affiliated investor, EDBI’s processes are institutional and term sheets may include strategic provisions tied to Singapore presence and operating commitments. Cycle times are months and partners expect active board engagement. Confirm reserves and follow-on policy explicitly given the firm’s preference for concentrated positions across the lifecycle.